Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Fatty liver disease is an increasingly recognized health problem in patients with type 2
diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT-2) inhibitors are a new
class of anti-diabetic agents that cause weight loss by inducing glycosuria. The effect of
SGLT-2 inhibitors on liver fat content is not evaluated. Empagliflozin is an orally active,
selective inhibitor of SGLT-2. We hypothesized that Empagliflozin, when added to standard
care for T2DM, would improve fatty liver disease. Therefore, the present study is planned to
evaluate the effect of Empagliflozin on the liver fat content.